Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Morel

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
BMC Infectious Diseases|September 28, 2024
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participantsMathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Rheumatology (Oxford, England)|December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional studyAlice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
Joint Bone Spine|June 28, 2011
TNF alpha antagonist therapy and safety monitoringThao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in RemissionJoanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
Annals of the Rheumatic Diseases|November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trialRenaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
JAMA|September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical TrialJacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Annals of the Rheumatic Diseases|December 1, 2016
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project ConsortiumPilar Brito-Zerón, Nihan Acar-Denizli, Margit Zeher, et al.
Clinical and Experimental Rheumatology|August 30, 2018
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project)Pilar Brito-Zerón, Nihan Acar-Denizli, Wan-Fai Ng, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
BMC Infectious Diseases|September 28, 2024
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participantsMathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Rheumatology (Oxford, England)|December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional studyAlice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
Joint Bone Spine|June 28, 2011
TNF alpha antagonist therapy and safety monitoringThao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in RemissionJoanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
Annals of the Rheumatic Diseases|November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trialRenaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
JAMA|September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical TrialJacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Annals of the Rheumatic Diseases|December 1, 2016
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project ConsortiumPilar Brito-Zerón, Nihan Acar-Denizli, Margit Zeher, et al.
Clinical and Experimental Rheumatology|August 30, 2018
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project)Pilar Brito-Zerón, Nihan Acar-Denizli, Wan-Fai Ng, et al.
Pageof 17